National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting, 76027 [2015-30750]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 234 / Monday, December 7, 2015 / Notices
Application No. 62/018,381, entitled
‘‘Aza-epoxy-guaiane derivatives and
treatment of cancer’’ filed June 27, 2014
(HHS Ref. No. E–090–2014/1–US–01);
and US Provisional Patent Application
No. 61/936,285, entitled ‘‘Aza-englerin
analogues and use in cancer therapy’’
filed February 5, 2014 (HHS Ref. No. E–
090–2014/0–US–01).
The patent rights in these inventions
have been assigned to the Government
of the United States of America and the
University of Hawaii.
The territory of the prospective StartUp Exclusive Evaluation Option License
Agreement may be worldwide, and the
field of use may be limited to
‘‘Development and commercialization of
aza-epoxy guaiane derivatives for
treatment of renal cancer.’’
Upon the expiration or termination of
the Start-up Exclusive Evaluation
Option License Agreement, ElexiMed
LLC will have the exclusive right to
execute a Start-Up Exclusive Patent
License Agreement which will
supersede and replace the Start-up
Exclusive Evaluation Option License
Agreement, with no greater field of use
and territory than granted in the Startup Exclusive Evaluation Option License
Agreement.
DATES: Only written comments and/or
applications for a license which are
received by the NCI Technology
Transfer Center on or before December
22, 2015 will be considered.
ADDRESSES: Requests for copies of the
patent application(s), inquiries,
comments, and other materials relating
to the contemplated Start-Up Exclusive
Evaluation Option License Agreement
should be directed to: Rose Freel, Ph.D.,
Licensing and Patenting Manager,
Technology Transfer Center, National
Cancer Institute, Riverside 5, Suite 400,
8490 Progress Drive, Frederick, MD
21702; telephone: 301–624–1257;
Facsimile: 301–631–3027; Email:
rose.freel@nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
Patent and Trademark Office or the
World Intellectual Property
Organization.
This
technology describes aza-englerins,
synthetic analogues of the natural
product Englerin A which displays
potent and selective anti-cancer
properties in several cancer cell lines.
The aza-englerins were developed as
novel cancer therapeutics and show
significant bioavailability after oral
administration in mice.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
18:36 Dec 04, 2015
Jkt 238001
The prospective Start-Up Exclusive
Evaluation Option License Agreement is
being considered under the small
business initiative launched on October
1, 2011 and will comply with the terms
and conditions of 35 U.S.C. 209 and 37
CFR part 404.7. The prospective StartUp Exclusive Evaluation Option License
Agreement and a subsequent Start-Up
Exclusive Patent License Agreement
may be granted unless the NCI receives
written evidence and argument, within
fifteen (15) days from the date of this
published notice, that establishes that
the grant of the contemplated Start-Up
Exclusive Evaluation Option License
Agreement would not be consistent with
the requirements of 35 U.S.C. 209 and
37 CFR part 404.7.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-Up Exclusive
Evaluation Option License Agreement.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: December 2, 2015.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2015–30752 Filed 12–4–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council for
Biomedical Imaging and Bioengineering.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
76027
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering, NACBIB, January, 2016.
Date: January 21, 2016.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: Report from the Institute Director,
other Institute Staff and Scientific
Presentations.
Place: The William F. Bolger Center,
Franklin Building, Classroom 1, 9600
Newbridge Drive, Potomac, MD 20854.
Closed: 1:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: The William F. Bolger Center,
Franklin Building, Classroom 1, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: David George, Ph.D.,
Acting Associate Director, Office of Research
Administration, National Institute of
Biomedical Imaging and Bioengineering,
6707 Democracy Boulevard, Room 920,
Bethesda, MD 20892.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://www.
nibib1.nih.gov/about/NACBIB/NACBIB.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
Dated: December 2, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–30750 Filed 12–4–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council on Aging.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
E:\FR\FM\07DEN1.SGM
07DEN1
]]>Agencies
[Federal Register Volume 80, Number 234 (Monday, December 7, 2015)]
[Notices]
[Page 76027]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-30750]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Advisory Council for Biomedical Imaging and Bioengineering.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council for Biomedical
Imaging and Bioengineering, NACBIB, January, 2016.
Date: January 21, 2016.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: Report from the Institute Director, other Institute
Staff and Scientific Presentations.
Place: The William F. Bolger Center, Franklin Building,
Classroom 1, 9600 Newbridge Drive, Potomac, MD 20854.
Closed: 1:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: The William F. Bolger Center, Franklin Building,
Classroom 1, 9600 Newbridge Drive, Potomac, MD 20854.
Contact Person: David George, Ph.D., Acting Associate Director,
Office of Research Administration, National Institute of Biomedical
Imaging and Bioengineering, 6707 Democracy Boulevard, Room 920,
Bethesda, MD 20892.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://www.nibib1.nih.gov/about/NACBIB/NACBIB.htm, where an
agenda and any additional information for the meeting will be posted
when available.
Dated: December 2, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-30750 Filed 12-4-15; 8:45 am]
BILLING CODE 4140-01-P
